Neuroscience
Positron Emission Tomography
100%
Amyloid
54%
Fluorine-18
44%
Alzheimer's Disease
35%
In Vivo
31%
Positron Emission Tomography
26%
Nicotinic Acetylcholine Receptor
23%
Radioligand
20%
Mild Cognitive Impairment
16%
Beta Amyloid
13%
Serotonin
11%
Cerebellum
10%
Binding Affinity
10%
Encephalopathy
10%
Altanserin
9%
Molecular Imaging
9%
Dementia Praecox
8%
Receptor Binding
8%
Gray Matter
7%
Late Life Depression
6%
5-HT1A Receptor
6%
Colony Stimulating Factor 1 Receptor
6%
Cannabinoid 1 Receptor
6%
Brain Imaging
6%
Pharmacokinetics
6%
Striatum
6%
Frontal Lobe
6%
In Vitro
6%
Benzothiazole
5%
Cognitive Disorders
5%
Iodine-125
5%
Eicosanoid Receptor
5%
Keyphrases
Positron Emission Tomography
56%
Amyloid Deposition
25%
Radiotracer
16%
Alzheimer's Disease
15%
Nicotinic Acetylcholine Receptor (nAChR)
13%
Radiosynthesis
12%
Methyl
11%
Pittsburgh Compound B
10%
Mild Cognitive Impairment
9%
Altanserin
9%
CSF1R
9%
Molecular Imaging
9%
Volume of Distribution
8%
Serotonin
8%
Transgenic Mice
8%
5-HTT
8%
PET Radiotracers
8%
Alzheimer's Disease Brain
7%
PET Imaging
7%
High Specific Activity
7%
Baboon
7%
Microglia
7%
Cyclic GMP
6%
Heptane
6%
Azabicyclo
6%
Occupancy
6%
Molar Activity
6%
Methoxy
6%
DCFBC
6%
Pyridinyl
6%
Late-life Depression
6%
Positron Emission Tomography-computed Tomography (PET-CT)
6%
Prostate-specific Antigen
6%
Conventional Imaging
6%
4-aminobenzoic Acid
6%
Rifampin
6%
Positron Emission Tomography Study
6%
Human Brain
5%
Plaque
5%
Phenyl
5%
Binding Potential
5%
High Affinity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Carbon 11
57%
Fluorine 18
50%
Tracer
29%
Nicotinic Receptor
23%
Amyloid
16%
Radioligand
16%
Alzheimer's Disease
14%
Prostate Specific Membrane Antigen
13%
Mouse
11%
Rifampicin
9%
Receptor
8%
Biodistribution
8%
Human Study
8%
Lipophilicity
7%
Prostate Cancer
7%
Pharmacokinetics
7%
Altanserin
6%
Dosimetry
6%
4-Aminobenzoic Acid
6%
Volume of Distribution
6%
Iodine-125
5%
Normal Human
5%
